CTLA4 and cancer: Recently, pan-cancer analysis by Charoentong et al. characterizing immune infiltrates across 20 cancer types provided a multigene predictor (“immunophenoscore”) of patient response to checkpoint blockade (CTLA-4 and PD-1 blockers) [17].